Neuronetics (STIM) Projected to Post Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Neuronetics to post earnings of ($0.13) per share and revenue of $29.07 million for the quarter.

Neuronetics Price Performance

Shares of NASDAQ STIM opened at $4.58 on Friday. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics has a 1-year low of $0.52 and a 1-year high of $5.92. The company has a market capitalization of $301.43 million, a price-to-earnings ratio of -3.72 and a beta of 1.92. The business has a 50-day moving average of $4.25 and a 200-day moving average of $2.71.

Insiders Place Their Bets

In related news, CEO Keith J. Sullivan sold 40,992 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.28, for a total value of $134,453.76. Following the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at approximately $4,209,427.36. The trade was a 3.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Stephen Furlong sold 17,307 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the transaction, the chief financial officer now directly owns 454,420 shares of the company’s stock, valued at $1,867,666.20. This represents a 3.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 100,369 shares of company stock worth $358,929 in the last quarter. 8.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group increased their price objective on shares of Neuronetics from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.